DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 performance and a series of favorable coverage decisions are expected to contribute further. Risks related to stiff competition persist.
This Zacks Rank #2 (Buy) company’s shares have lost 7.3% so far this year compared with the industry’s 11.6% decline. The S&P 500 Index has gained 1.9% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $24.23 billion. It projects a 20.6% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed in one, the average surprise being 3.82%.
Let’s delve deeper.
Positive Drivers
Expanding Addressable Market: DexCom’s long-term growth trajectory is anchored in a significant expansion of its addressable market, particularly among type 2 non-insulin patients. Management highlighted that Medicare coverage for this population could unlock access for nearly 12 million additional patients, with private payer coverage already progressing.
Clinical evidence, registry data and upcoming randomized trial readouts further support adoption in this segment. Given strong utilization trends among early adopters, this expansion represents a structural demand driver that could sustain double-digit growth for multiple years.
G7 15-Day Platform Enhances Product Differentiation: The rollout of the G7 15-day sensor represents a meaningful innovation cycle, improving wear duration, accuracy and patient convenience. Early feedback from physicians and users has been highly positive, reinforcing DexCom’s positioning as a premium CGM provider.
The platform also supports margin expansion through lower per-day manufacturing costs and supply-chain efficiencies. Over time, as the installed base transitions to this platform globally, the company expects both improved customer retention and stronger gross margins, creating a dual benefit of growth and profitability.
Strong International Growth With Long-Term Upside Potential: DexCom’s international business grew 18% reportedly (15% organic) in the fourth quarter, outperforming the U.S. market and demonstrating strong momentum in markets such as Germany, France and the United Kingdom.
Expanded reimbursement, particularly for type 2 patients in Europe, is accelerating adoption. Management emphasized that international markets could eventually surpass the United States in size, given lower current penetration and significant untapped demand. Continued expansion into new geographies, combined with a tiered product portfolio strategy, positions DexCom for sustained global share gains over the long term.
Risks
Pricing Pressure and Volume-Price Trade-Off: As DexCom expands access, particularly in the type 2 non-insulin segment, it faces inherent pricing pressure from payers. Management acknowledged ongoing volume-price trade-offs during annual negotiations, with pricing largely stable but constrained.
While increased patient volumes can offset pricing pressure, broader reimbursement, especially under Medicare, could introduce further pricing compression through competitive bidding mechanisms. This dynamic creates a structural challenge where long-term growth is increasingly volume-driven, potentially limiting average selling price expansion and moderating revenue growth quality.
Margin Volatility From Ireland Manufacturing Ramp-Up: DexCom’s planned Ireland manufacturing facility introduces near-term cost headwinds, as operating expenses related to staffing, validation and depreciation will be incurred before full production ramp.
Management expects these costs to temporarily weigh on margins, particularly as fixed overhead shifts into cost of goods sold in late 2026. While the facility enhances long-term capacity and efficiency, the transitional phase creates margin volatility and execution risk, especially if ramp timelines or utilization levels fall short of expectations.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
Estimate Trend
DexCom has witnessed a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $2.49.
The consensus mark for the company’s first-quarter revenues is pegged at $1.18 billion, indicating a 13.6% improvement from the year-ago quarter’s reported number. The consensus estimate for first-quarter earnings is pinned at 47 cents per share, implying an improvement of 46.9% year over year.
Other Stocks to Consider
Some other top-ranked stocks from the same medical industry are Pacific Biosciences of California PACB, Globus Medical GMED and Biodesix BDSX.
Pacific Biosciences of California, currently flaunting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $45 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings decline rate of 1.9% against the industry’s 11.4% growth. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.7%.
Globus Medical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $1.28, which outpaced the Zacks Consensus Estimate by 20.8%. Revenues of $826 million surpassed the Zacks Consensus Estimate by 4.9%.
GMED has an estimated long-term earnings growth rate of 9.6% compared with the industry’s 14% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 13.2%.
Biodesix, currently carrying a Zacks Rank of 2, reported a fourth-quarter 2025 adjusted loss per share of 49 cents, which beat the Zacks Consensus Estimate by 53.33%. Revenues of $29 million beat the Zacks Consensus Estimate by 14.1%.
BDSX has an estimated earnings growth rate of 22.5% for 2026 compared with the industry’s 12% rise. The company beat earnings estimates in two of the trailing four quarters, missed in one and met in the other, with the average surprise being 16.64%.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report
Biodesix, Inc. (BDSX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).